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Abstract
Background: Physical activity (PA) and exercise have become an accepted and valued component of cystic fibrosis
(CF) care. Regular PA and exercise can positively impact pulmonary function, improve physical fitness, and enhance
health-related quality of life (HRQoL). However, motivating people to be more active is challenging. Supervised exercise
programs are expensive and labour intensive, and adherence falls off significantly once supervision ends. Unsupervised
or partially supervised programs are less costly and more flexible, but compliance can be more problematic. The primary
objective of this study is to evaluate the effects of a partially supervised exercise intervention along with regular
motivation on forced expiratory volume in 1 s (FEV1) at 6 months in a large international group of CF patients. Secondary
endpoints include patient reported HRQoL, as well as levels of anxiety and depression, and control of blood sugar.
Methods/design: It is planned that a total of 292 patients with CF 12 years and older with a FEV1≥ 35% predicted
shall be randomised. Following baseline assessments (2 visits) patients are randomised into an intervention and a
control group. Thereafter, they will be seen every 3 months for assessments in their centre for one year (4 follow-up
visits). Along with individual counselling to increase vigorous PA by at least 3 h per week on each clinic visit, the
intervention group documents daily PA and inactivity time and receives a step counter to record their progress within
a web-based diary. They also receive monthly phone calls from the study staff during the first 6 months of the study.
After 6 months, they continue with the step counter and web-based programme for a further 6 months. The control
group receives standard care and keeps their PA level constant during the study period. Thereafter, they receive the
intervention as well.
Discussion: This is the first large, international multi-centre study to investigate the effects of a PA intervention in CF
with motivational feedback on several health outcomes using modern technology. Should this relatively simple
programme prove successful, it will be made available on a wider scale internationally.
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Background
Regular physical activity (PA) and exercise have become an
accepted and valued part of cystic fibrosis (CF) care [1–3].
Two supervised exercise intervention studies have proven
that regular vigorous exercise can positively impact forced
expiratory volume in 1-s (FEV1) [4, 5], the single best prog-
nostic factor for CF [6]. It has been suggested that the posi-
tive effects of regular exercise on pulmonary function
might be moderated by improved airway clearance from se-
cretions [1] and strengthening of respiratory muscles [7].
However, the exact mechanisms are unclear.
Supervised exercise interventions are expensive, not eas-
ily implemented in regular patient care and long-term ad-
herence to supervised programs is often low [8]. In
particular, long-term adherence following supervised exer-
cise programs can be problematic [7] as such programs
are often relatively monotonous and do not respond to
the individual preferences of participants. Involving pa-
tients in decisions making around their exercise programs
may overcome this barrier to sustainability [9, 10].
Exercise programs which are home-based and un-
supervised or partially supervised have several advan-
tages over supervised programs [7]: i) the programme
can be easily implemented; ii) the patients can choose
activities based on their personal preferences; iii) the ac-
cessibility of the activities with respect to location and
time is much greater; iv) physical activities can be
planned together with family members or friends; and v)
the costs per patient and travel time commitments are
much lower compared to a supervised programme.
These advantages may enhance long-term positive
changes in lifestyle not seen in standard supervised exer-
cise programs [11]. Hebestreit et al., have shown that a
partially supervised exercise intervention can improve
forced vital capacity (FVC), exercise capacity and health-
related quality of life (HRQoL) in CF [7]. Furthermore,
this study demonstrated lasting benefits for these
variables at 18 and 24 months after the end of the inter-
vention [7]. If the benefits of such a partially supervised
intervention can be applied to a wider population of CF
patients with different health beliefs who are cared for by
different health care systems, this would have significant
implications for long-term outcomes in CF patients.
This randomised, parallel group study evaluates our
hypothesis that a partially supervised PA programme
paired with motivational feedback aimed at increasing
vigorous habitual PA by at least 3 hours per week, can
improve FEV1 and that this can be sustained over the
subsequent six-month timeframe.
Methods
Study design
This study is an international multi-centre, randomised
controlled trial with a parallel group design (Clinical
trials.gov Identifier: NCT01744561). The study is con-
ducted across CF centers in eight countries (Austria,
Canada, France, Germany, Netherlands, Switzerland,
United Kingdom and the United States). Patients are
randomly allocated to either a partially supervised PA
intervention or control intervention (no PA), see Fig. 1.
Due to the nature of the intervention, blinding of partic-
ipants is not possible. However, blinding of care team
members and controls with respect to measurement re-
sults are done whenever possible. The study is con-
ducted in full conformance with the principles of the
“Declaration of Helsinki” (as amended in Tokyo, Venice
and Hong Kong) and with the EC/ICH-Guidelines on
Good Clinical Practice. The study is restricted to pa-
tients who provided written informed consent.
Study population
To be eligible for enrolment, patients with CF from all
participating countries and centres who meet all
Fig. 1 Study design and assessment time points
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inclusion criteria will be invited to participate in the
study: i) Confirmed diagnosis of CF based on either two
CF-causing mutations and/or a sweat chloride concen-
tration during two tests of > 60 mmol/l; ii) age ≥ 12 years;
iii) FEV1 ≥ 35% predicted [12]; iv) Access to the internet.
Patients are excluded from the study if they have at least
one of the following exclusion criteria: i) Participation in
another clinical trial up to 4 weeks prior to the first baseline
visit; ii) Status post lung transplantation; iii) Pregnancy/
Breastfeeding; iv) Inability to exercise; v) More than 4 h of
reported vigorous PA’s per week currently or up to 3 months
prior to baseline measurements and not already planned
within the coming 6 months; vi) Unstable condition affect-
ing pulmonary function or exercise participation (i.e., major
haemoptysis or pneumothorax within the last 3 months,
acute exacerbation and iv-antibiotics during the last
4 weeks, unstable allergic bronchopulmonary aspergillosis,
planned surgery, listed for lung transplantation, major
musculoskeletal injuries such as fractures or sprains during
the last 2 months, others according to the impression
of the medical doctor); vii) Cardiac arrhythmias with
exercise; viii) Requiring additional oxygen with exer-
cise; ix) Recent diagnosis of diabetes 3 months prior
to screening or at screening; x) Recent changes in
medication 1 month prior to screening (steroids, ibu-
profen, inhaled antibiotics, mannitol, DNAse, hyper-
tonic saline); xi) At least one G551D mutation and
not on ivacaftor (VX770) yet but planning to start
the drug or planning to stop ivacaftor and xii) Colon-
isation with Burkholderia cenocepacia.
Randomisation
Participants are randomly allocated to the intervention
and control group in a one-to-one ratio using block-
randomisation (block sizes of 4) and stratified by coun-
try and according to whether FEV1 is below or ≥70%
predicted (moderate/severe lung disease vs. normal/mild
lung disease) [12]. A person not involved in the study
created a computer-generated randomisation list that
was implemented into the database (REDCap, Research
Electronic Data Capture) by a person from the Clin-
ical Trials Unit Bern, Switzerland, offering administra-
tive database support. Randomisation is done at each
study site within the database (REDCap Software-
Version 5.9.2 – © 2014 Vanderbilt University Belgium)
allowing complete allocation concealment. The partici-
pant’s mean FEV1 value in % predicted from both baseline
visits (1a and 1b) is entered and a group allocation is
returned automatically. We implemented a training data-
base with identical electronic case report forms (eCRF’s)
and data collection instruments to allow study site investi-
gators to familiarise themselves with the database before
entering real patient data. The database allows entering
patient data on-line from different study sites into eCRF’s.
As lung function and clinical status are fundamental in
this study and may change within short time periods, the
intervention starts immediately after randomisation has
taken place.
Withdrawal from study
The trial as a whole will be terminated prematurely if
one or more serious adverse events invalidate the
earlier positive benefit-risk assessment or when the
time schedule cannot be met (e.g., more than doub-
ling of recruitment time). All withdrawals are docu-
mented and the reason for withdrawal is recorded.
All withdrawals will be discussed in the final report
of the study. No attempt is to replace patients who
withdraw from the trial.
Physical activity intervention
Intervention arm
Participants in the intervention group are asked to add
at least 3 hours of vigorous PA’s per week to their base-
line activity. For the purposes of this study, vigorous PA
is defined as activity that results in the participant
breathing rapidly, only able to speak in short phrases,
where heart rate is increased substantially, and sweating
is present [13]. Including the activities already present at
the baseline assessment, this should include at least
30 min of strength building exercises and 2 hours of aer-
obic PA’s per week. The remaining time can be attrib-
uted according to the participant‘s preferences. PA bouts
lasting 20 min or longer will be counted with respect to
total weekly training time.
At the second baseline visit, following randomisation,
the participants in the intervention group will undergo
an assessment of their preferences and motivation,
followed by counselling immediately and at all subse-
quent study visits scheduled every 3 months. The coun-
selling and activity assessments are done in each centre
by a designated team member (physiotherapist or exer-
cise specialist) who receives prior training so that a
standardised approach is ensured. The participants
complete a self-administered activity questionnaire and a
structured interview using a standardised motivational
interview form is carried out to assess the participant’s
likes and dislikes with respect to PA’s and to identify
possible barriers and determine the motivation (using a
10-point Likert Scale) of the participant to start specific
activities and to make individualised PA recommenda-
tions. Based on the information from the questionnaire
and interview, the physiotherapist/exercise specialist and
the participant/his guardians engage in a dialogue identi-
fying additional PA’s that are strength building and/or
promoting aerobic fitness that will result in an additional
3 h per week of these activities at a vigorous level.
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Participants of the intervention group are also told a tar-
get heart rate range corresponding to 60–80% of peak
oxygen uptake (VO2peak) for vigorous continuous aer-
obic type activities [13]. VO2peak is determined during
incremental exercise tests at baseline and after 6 months.
Patients also receive training how to determine heart
rate during exercise.
Participants receive further motivation by being equipped
with a three-axial pedometer (Omron HJ-322 U-E). Partici-
pants are instructed to wear the pedometer on a daily basis
and they are asked to complete a web-based log (http://
www.activate-cf.org/) on a daily basis. The user interface
of the website is programmed to allow access from
classical personal computers, palm tops, tablets and
smartphones. Participants are asked to document
daily steps from their pedometer and training activ-
ities in their web-based logbook, using an individual
pseudonym login that is provided by their study
centre. In the web-based log book, data on i) vigor-
ous PA’s performed that day (type of PA, duration), ii)
total daily step count and exercise step count (steps
with estimated energy expenditure of at least 3 meta-
bolic exchange units-METS), and iii) time in seden-
tary activities (i.e. watching TV, playing video games
without activity components, computer time, driving,
taking a nap/sleeping) are entered.
The central monitoring unit in Wuerzburg, Germany
is responsible for monitoring data entries on the web-
based log. The participant’s CF centre will be notified if
there have been no completed entries into the system
for the previous 3 days or longer. The participants re-
ceive a “reminder” message on his or her mobile phone
or via email if no entries have been made for three
consecutive days. If there are no entries for a whole
week, participants are contacted by phone from their
centre’s designated activity contact person (i.e., physio-
therapist, exercise specialist).
Participants complete a PA questionnaire at all clinic
visits. The web-based training logs are checked at the
clinic visits and discussed with the participant by the
physiotherapists/exercise specialist. The physiotherapist/
exercise specialist utilises this information, along with
the web-based logs and the interview to provide exercise
counselling at every visit to the centre. If necessary, a
new activity plan will be created.
There are scheduled phone contacts after 1, 2, 4
and 5 months by the physiotherapist/exercise special-
ist into the training to discuss progress and to re-
counsel the participants PA plan. During the monthly
scheduled telephone contacts, the participant is asked
about his or her weekly exercise activities and the
written activity agreement is reviewed. Likewise, the
web-based activity log is discussed with the partici-
pant. If one or more goals of the plan have not been
met or problems have been encountered or new
activity ideas come up, the plan is modified. The
structured interview forms available for the initial
counselling are used to assist as needed. In case of
admission to the hospital, physical exercise is in-
cluded in the in-patient treatment (the treating phys-
ician needs to decide what is possible).
After the six-month assessment, participants of the
intervention group will keep their pedometers and still
have access to the web-system to report and view their
PA data. Centre staff meets with participants as part of
routine care and as deemed necessary by the treating
physician. Staff members do not receive the data col-
lected, unless clinically relevant, such as a change in gly-
caemic control, and advise the patient based on the
information that they gather from the patient.
Control arm
The control group is instructed to keep their PA level
constant over the 12 months of the study. Controls
do not get informed about their fitness level during
the exercise test nor receive any interpretation of the
test results unless a finding is detected which requires
medical attention. They are not be given an evalu-
ation of their answers to the activity questionnaires
nor on their pedometry (or accelerometry) data. At
the closeout visit after 12 months, controls receive a
pedometer and access to the web-based log and get a
PA counselling as the intervention group had received
at baseline.
Recruitment and study procedures
This RCT is currently ongoing. The first patient was
enrolled on 16th July 2014 and the estimated study com-
pletion date is December 2018.
At enrolment, a clinical assessment is performed for all
patients using standardised procedures. Table 1 provides
an overview about all study visits and assessments
throughout the study. Two baseline visits (1b & 1b) are
scheduled to evaluate inclusion and exclusion criteria. Fol-
lowing randomisation on baseline visit 1b, participants are
seen every 3-months during the 12-month study period (4
follow-up visits, see Fig. 1).
Study endpoints and measurements
The primary outcome measure is the difference be-
tween the changes in FEV1 (in % predicted) from
baseline (using the average of the two baseline mea-
surements) to 6 months in the intervention group
compared to controls. Secondary outcomes include
change in aerobic exercise capacity (VO2peak), PA,
HRQoL and others listed in Table 2. Vital signs, an-
thropometric characteristics (weight, height, skinfolds)
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are measured at each study visit using standardised
procedures.
Pulmonary function
Spirometry and body plethysmography is performed
according to ERS and ATS guidelines [14, 15] at all
study visits pre-bronchodilation. FEV1 and forced vital
capacity (FVC) are expressed as %predicted using ref-
erence values published by Quanjer et al. [12]. The
degree of air trapping (Residual Volume/Total Lung
Capacity) is derived from lung volumes.
Cardiopulmonary exercise testing (CPET)
A continuous incremental cycle ergometer cardiopulmo-
nary exercise test using the Godfrey protocol [16] is per-
formed in accordance to a statement on exercise testing in
CF [17]. Maximal aerobic power (Wattmax) and VO2peak
will be expressed in percent of predicted [16, 18].
Table 1 Data collected at baseline and follow-up
Baseline 3 month 6 month 9 month 12 month
Visit 1a 1b 2 3 4 5
Time −21 d (±7 d) Day 1 90 d (±14 d)a 180 d (±14 d)a 270 d (±14 d)a 360 d (±14 d)a
Informed consent X
Medical history X
In−/exclusion criteria X X
Physical examination, vital signs X X X X X X
Physical (in)activity history X
Anthropometry X X X X X X
Spirometry X X X X X X
Body plethysmography X X X X X X
Oral glucose tolerance test X X
Cardiopulmonary exercise testing X X X
Pedometry X (X)b X (X)b X
Physical activity questionnaire
(7-day recall)
X X X X X X
Exacerbations, upper respiratory
tract infections, antibiotic use,
adverse events
X X X X X X
CFQ-R questionnaire X X X
DASS questionnaire X X X
EMI 2 questionnaire X X X
Diary, 3-months retrospective
questionnaire,
Interviewc, Patient-initiated
contact
X X X X X X
For Intervention group only
Exercise motivation interviewc X X X X X X
Web-based diary, paper diary,
pedometerd
XXXXXX
Schedule of measurements for the sub-studies in selected centers
Baseline 3 month 6 month 9 month 12 month
Visit 1a 1b 2 3 4 5
Time −21 d (±7 d) Day 1 90 d (±14 d) 180 d (±14 d) 270 d (±14 d) 360 d (±14 d)
Accelerometrye X X X
Multiple breath washoute X X X X
DXAe X X X
Scintigraphye X X
CFQ-R Cystic Fibrosis Questionnaire-revised, DASS Depression and Anxiety Stress Scales, DXA Dual energy X-ray absorptiometry, EMI Exercise Motivational Inventory
aIn case of an exacerbation the visit will be postponed until 14 days after oral or intravenous antibiotic treatment of exacerbation has been stopped
bIntervention group only
cAt each visit and at scheduled telephone contacts
dOver the whole intervention period of 12 months
eIn selected centres only
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Physical activity
Daily PA is measured using a tri-axial Omron HJ-322
pedometer for 7 days prior to baseline visit 1b and
prior to the 6-months and 12-months visits. The 7-
day recall questionnaire is used to assess time spent
in the PA categories ‘hard’ and ‘very hard’. The ques-
tionnaire is a feasible and valid instrument to assess
PA in people with CF [19].
Health-related quality of life (HRQoL)
HRQoL is assessed using the adolescent/adult version of
the Cystic Fibrosis Questionnaire (CFQ-R), a validated
CF-specific instrument [20, 21].
Psychological health
Psychological health is assessed using the Depression
Anxiety Stress Scales (DASS), a 42-item self-report
Table 2 Primary, secondary and explorative outcome measures
Outcome Variable Measurement
Primary endpoint
• Lung function FEV1% predicted Spirometry
Secondary endpoints
• Exercise capacity VO2peak % predicted CPET
Wattmax % predicted CPET
• Physical activity Steps per day Pedometry
Exercise steps per day Pedometry
Reported physical activity (min per day) 7-day recall questionnaire
• Pulmonary function FEV1% predicted Spirometry,
Bodyplethysmography
FVC % predicted
RV/TLC %
• Exacerbation Time to first exacerbation Questionnaire
(modified Fuchs criteria) and physician
assessment
• Body composition Body fat Skinfolds
Lean body mass Skinfolds
• Health-related quality of life Scales Questionnaire (CFQ-R)
• Depression, anxiety and stress scales Scales Questionnaire (DASS)
• Glycaemic control Plasma glucose concentrations (fasting, 1
and 2 h after standardised glucose load)
Oral glucose tolerance testa
Explorative endpoints
• Physical activity Moderate and vigorous physical activity Accelerometryb
• Infections Number of upper respiratory tract
infections
3-months retrospective questionnaire,
Interviews, Diary and telephone calls
• Antibiotic therapy Days on additional oral/intravenous
antibiotics
3-months retrospective questionnaire,
Interviews, Diary and telephone calls
• Body composition Body mass index Based on measured height and weight
• Lung function Lung clearance index Multiple breath washoutc
• Mucociliary clearance Mucociliary clearance Scintigraphyd
Safety endpoints
• Adverse events Adverse events at least possibly related
to exercise (e.g., sprains, fractures etc)
Judged by investigator
Others
• Compliance with exercise Exercise goal of 3 additional hours of
vigorous activity per week
Baseline assessment and web-based diary
CFQ-R Cystic Fibrosis Questionnaire-revised, CPET cardiopulmonary exercise test, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, RV/TLC residual
volume/total lung capacity, VO2peak peak oxygen uptake, Wattmax maximal aerobic power
aonly in patients without cystic fibrosis related diabetes
bonly in European centers
cselected centers only
dUS centers only
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questionnaire that has been validated in clinical and
non-clinical samples [22, 23].
Glycaemic control
Assessment of glycaemic control and potential diagnosis
of cystic fibrosis related diabetes (CFRD) is performed
using the oral glucose tolerance test after an 8 h fast ac-
cording to a published consensus statement [24]. Blood
samples are collected in a fasting state, and 1 and 2 h
after the glucose challenge.
Exacerbations
Time to, number of and time with pulmonary exacerba-
tions with and without hospitalisations, number of
pulmonary exacerbations requiring intravenous anti-
biotic treatment, number of days on intravenous anti-
biotic therapy for pulmonary exacerbations and time to
first intravenous antibiotic treatment for pulmonary ex-
acerbations are assessed. The information is derived
from a diary kept by each participant, 3-months retro-
spective questionnaires completed at each study visit,
interviews at each study visit and scheduled telephone
contact, and information provided by the participants at
participant-initiated contacts. Each episode of pulmon-
ary exacerbation defined as new or changed antibiotic
therapy based on modified Fuchs criteria is recorded
[25]. In addition, we note the number and times of out-
patient visits to a medical doctor, clinic or hospital for
CF-related complications with documentation of rea-
sons. This includes the number of unplanned hospitali-
sations and their respective duration and reasons.
Upper respiratory tract infection (URTI)
As exacerbations, URTIs are identified from participants’
diary, from 3-months retrospective questionnaires
completed at all clinic visits, from interviews at study
visits and from telephone contacts. URTI are defined as
at least 3 consecutive days of runny nose and sore
throat.
Courses of unscheduled antibiotics
Antibiotic use is documented at all clinic and study visits
as well as in participants’ diaries and antibiotics courses
(intravenous, oral or inhaled) are counted. In case of ex-
acerbation, planned study visits are postponed until
14 days after oral or intravenous antibiotic treatment of
exacerbation has been stopped.
Substudies
Accelerometry
In European countries, PA is assessed by an accelerom-
eter (Actigraph GT1M or wGT3X, Pensacola, FL, USA),
which is worn at the right hip over 7 days at baseline
and prior to the 6 and 12-months study visits. The
sampling epoch is set at 5 s and data are included if at
least 4 full days (at least 3 weekdays and one weekend
day) of measurements with a minimum of 10 h for the
weekdays and 10 h for the weekends are measured [26].
Overall PA is expressed as average counts/min and time
(min/day) in light, moderate and vigorous PA according
to validated cut-off levels [27–29].
Multiple breath washout
Lung clearance index is determined using commercially
available systems based on nitrogen washout (EasyOne-
Pro Lab, ndd Medical Technologies, Zurich, Switzerland;
ECO MEDICS AG, Dürnten, Switzerland) in centres
with access to this or similar technology. Measurements
are performed prior to spirometry and body plethysmog-
raphy following the manufacturers’ instructions. The
methodology has proven to be feasible in multi-centre
trials [30].
Dual energy X-ray absorptiometry
Body composition and bone parameters are measured
using dual-energy X-ray absorptiometry in Canadian and
Swiss participants. Body composition is assessed by the
three-compartment model, including fat mass, bone
mineral content, and bone mineral free lean tissue. Bone
mineral content and bone mineral density values are z-
transformed using pubertal stage- and gender-specific
means and standard deviations [31].
Mucociliary clearance
Mucociliary clearance (MCC) is measured using nuclear
medicine scans at baseline (visit 1a), immediately after a
submaximal exercise test (visit 1b), and then prior to
their maximal CPET at patient’s 6-month study visit, to
investigate the acute effects of exercise and the effects of
increased activity and vigorous PA over a 6-month
period on mucociliary clearance.
Monitoring and quality assurance
Standard operational procedures (SOP) for all the
methods used in the study are available in English.
Moreover, essential parts of the SOPs are translated in
all national languages of participating countries. A site
initiation visit takes place at each center prior to the en-
rolment of the first patient in the study. A close out visit
takes place when the last study participant at each center
has completed the study.
Central data monitoring of REDCap database entries
and on site monitoring are done for the majority of
database entries, especially inclusion and exclusion
criteria and study outcomes including safety data to assure
high quality data. In particular, all lung function data en-
tries and pseudonymized pulmonary function reports
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(primary endpoint FEV1) are checked for accuracy and
correctness according to ATS/ERS standards [14, 15].
A close out visit takes place when the last study
participant at each center has completed the study.
Data safety monitoring board (DSMB)
For this study a DSMB Safety Board was implemented.
Each serious safety issue is reported to the Board within
72 h. The safety board can request an interim analysis
and can stop the study in case of serious safety issues.
Sample size calculation
This study aims to enrol 292 patients with CF. The sam-
ple size is calculated based on the primary endpoint, i.e.,
change in FEV1 from baseline to 6 months between the
intervention and control group. Two hundred two sub-
jects with CF will be randomised in a 1:1 ratio to the
intervention and the control group. Assuming a 5%
screen failure rate, about 308 patients need to be
screened. With an estimated 20% dropout rate after ran-
domisation, this sample size would allow to detect a dif-
ference between intervention and control group after
6 months in FEV1 of 3% predicted (absolute change)
with a power of 80% and a type 1-error probability of
5%. We expect that, by using stringent criteria to meas-
ure FEV1 within this study and by averaging two
measurements 2–4 weeks apart to obtain the baseline
value, we can bring down the standard deviation of the
changes in FEV1 within each group from previously ob-
served 10% to approximately 8%.
Statistical analysis
Descriptive analyses using means and standard deviations,
medians and interquartile ranges or means and 95% confi-
dence intervals (CI’s) will be used for continuous variables
as appropriate. Frequencies and proportions with 95% CI’s
will be used for categorical variables. Primary analyses will
be performed according to intention-to-treat (ITT) with
all participants who were originally allocated by random-
isation and those who dropped out from the study. ITT
main analysis and analyses on secondary outpoints will be
done including missing data imputations by multiple
imputation, inverse probability weighing or mixed models
as appropriate.
Additionally, we will perform sensitivity analyses using
the per protocol set and run analyses based on reported
and assumed compliance. The analysis of reported com-
pliance will include all patients sufficiently compliant
with the protocol and include those randomised into the
intervention group with the addition of at least 2/3 of
training volume (e.g., the addition of 2 h per week of
vigorous PA) and compare to those randomised into the
control group with no more than 30 min of extra vigor-
ous PA per week during the period of interest than at
baseline. The analysis on assumed compliance will in-
clude those from the intervention group with an in-
crease of 5% and more of VO2peak from baseline as
marker of compliance with the programme and compare
to those randomised into the control group with less
than 5% increase of VO2peak from baseline as marker of
compliance with restraining from training.
The secondary efficacy endpoints will be analysed ac-
cording to the main model described above. This in-
cludes the 0 to 6 months and the 0 to 12 months’ time
periods for most variables, and the effects of the inter-
vention on the change in FEV1 over 12 months, and the
change in FEV1 between month 6 and month 12. Like-
wise, the change in glucose levels 1 and 2 h after a
standardised glucose load between baseline and 9 months
will be compared between groups. The endpoint “time
to first exacerbation” will be analysed using a Cox pro-
portional hazard model, while Poisson regression will be
used for “number of upper respiratory tract infections”.
The frequency of study participants developing diabetes
mellitus between baseline assessments and 9-months
follow-up will be compared between groups using chi
square statistics. For safety endpoints, data will be moni-
tored throughout the study for all patients. Analysis will
be performed on total number of events and type of event
(fracture, sprain, hypoglycaemia, haemoptysis, pneumo-
thorax, etc.). The change from 6 to 12 months for all
secondary outcomes and for the other explorative end-
points will be analysed with the main model described
above except for “days on oral / intravenous antibiotics”
which will be analysed using Poisson regression.
For the main analysis, the statistician and the PI will
have full access to the dataset including the DSMB.
Later, for secondary analysis, data will be shared among
national coordinators.
Discussion
This is the first large international randomised con-
trolled trial to study the effects of regular vigorous PA
with motivational feedback on important clinical,
physiological and patient-reported outcomes in CF. Pre-
vious exercise training studies in CF were mostly of low
to moderate methodological quality with small numbers
of patients and conducted over short periods of time [3].
While the positive effects of exercise training and PA in-
terventions on aerobic exercise capacity are predomin-
antly consistent among studies, the effects on HRQoL
and pulmonary function including FEV1 are less clear
[3]. Two supervised exercise interventions demonstrated
that regular vigorous exercise has the potential to
positively impact FEV1 [4, 5]. These data are supported
by observational studies, showing that regular PA is as-
sociated with a slower progression of FEV1 decline over
time [32, 33]. Despite the limitations of FEV1 as clinical
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endpoint [34], FEV1 is the most commonly used end-
point in clinical trials and still the single best prognostic
factor for CF [6]. The main aim of our study is to evalu-
ate whether regular vigorous habitual PA can prevent
deterioration of FEV1 decline over time that is much
more clinically relevant than to demonstrate short-term
improvements.
Our secondary aim is to study other important end-
points such as bone health, pulmonary exacerbations,
glycaemia control and patient-reported outcomes such
as HRQoL, depression and anxiety that have been rarely
investigated in exercise training and PA interventions in
CF [3]. Some of these endpoints have been previously
investigated in cross-sectional, observational and/or
small randomised controlled trials showing some benefi-
cial effects of PA on bone health [35], glycaemic control
[36] and hospitalisation days [33], but these data need to
be further substantiated by a large randomised con-
trolled study and ideally including patients with a broad
age range and disease severity to be representative for
the overall CF population. The focus of patient-reported
outcomes is very important and in the past has been
often neglected in trials.
A critical point in each PA intervention study espe-
cially in chronic disease is adherence and compliance of
the patients. Using pedometers to provide feedback on
daily PA can enhance motivation to exercise [37] and
has been shown to be effective in activity programs ad-
dressing people with a variety of chronic health condi-
tions (10) including youth [38] and patients with chronic
obstructive pulmonary disease [39]. Providing additional
feedback on exercise behaviour by keeping a diary as
well as giving personal feedback via a SMS message to
the cellular phone, email or telephone also enhanced
adherence to a home-based exercise programme that
was partially supervised [40, 41].
The major strength of the current investigation is the
inclusion of a heterogeneous study population with a
broad range of disease severity (FEV1 ≥ 35% predicted)
and recruited from eight different countries in Europe
and Northern America. The use of modern technology
(step counters and web-based diary) for PA monitoring
is unique to exercise studies in this patient population
and will provide new insights into the usefulness and
feasibility of these wearables.
Limitations
Due to the nature of a partially supervised study, adher-
ence to PA and data entries in the web-based diary
cannot be fully controlled. However, objective measures
of exercise capacity using CPET and PA (substudy using
Actigraph accelerometry) will be used to verify training
effects after 6 and 12-months and will provide an
indication of whether study participants adhered to their
training schedule or not. Blinding of study participants
to minimise bias is not possible in PA intervention stud-
ies, but outcome assessors are blinded, whenever pos-
sible. A selection bias towards a physically active CF
population may occur, because patients who are physic-
ally active in their daily lives might be more likely to par-
ticipate in this trial.
Patient recruitment for long-term PA interventions is
challenging [5], in particular in rare diseases such as CF.
Moreover, there are several recent drug trials on the
effects of CF transmembrane conductance regulator cor-
rector and potentiator therapy that might interfere with
the ACTIVATE-CF trial. Major efforts have been done
with respect to study center recruitment. The study is
currently running in > 20 specialised CF centers in eight
countries in Europe and Northern America. The first
study participant was enrolled in June 2014 and the last
study participant is expected to complete the last study
visit in June 2018.
This study could make an important contribution to
the knowledge on the effects of regular vigorous PA on
several important health outcomes in CF. In particular,
the use of modern PA monitoring and motivational feed-
back embedded in the intervention will enhance our
understanding on the feasibility and usefulness of these
tools with respect to long-term PA adherence.
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